Keyword: Ajovy

After a year as the second-highest-paid biopharma exec , Teva CEO Kåre Schultz got a big pay cut in 2019—with an extension to ease the sting.

Despite its CGRP rivals having a head start, Lundbeck is confident it can succeed with Vyepti, an exec said.

Teva's Ajovy rollout just scored a big win in England, thanks to a recommendation from cost watchdogs there.

With CGRPs on the rise, Allergan's Botox is holding onto neurologist support in migraine patients. That preference could be a big win for AbbVie.

Now that its global restructuring has wrapped, Teva is homing in on revenue growth, with branded meds Ajovy and Austedo at the center of its plans.

Now that Teva's Ajovy has an autoinjector FDA approval to match its rivals, can the drug actually score the 25% market share execs are hoping for?

Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.

Amgen had a head start on the CGRP race with its first-in-class approval for Aimovig, but now it's slipped under 50% total market share.

Debt-rating firm Moody's revised its Teva outlook from "stable" to "negative" as the company deals with multiple challenges.

Hard on the heels of its CGRP migraine competitors, Eli Lilly’s Emgality has been looking for a leg up. Solid data in preventing migraines as a follow-up treatment could do the trick.